In a 53‑year‑old woman with benign paroxysmal positional vertigo, are cinnarizine and betahistine appropriate as first‑line therapy, and what short‑term dosing and duration should be used if they are employed for symptom relief?

Cinnarizine and Betahistine Are NOT Appropriate First-Line Therapy for BPPV

Neither cinnarizine nor betahistine should be used as first-line treatment for benign paroxysmal positional vertigo—canalith repositioning procedures (CRPs) are the definitive treatment, and medications are reserved only for immediate symptom relief of nausea, not for treating the underlying condition. 1

Why These Medications Should Not Be First-Line

The 2017 AAO-HNS Clinical Practice Guideline explicitly states that medications are not used for BPPV treatment other than for relief of immediate distress, such as nausea 1. The guideline emphasizes that BPPV is a mechanical problem (displaced otoconia crystals) requiring a mechanical solution (repositioning maneuvers), not pharmacotherapy 1.

Evidence Against Routine Use:

• Cinnarizine: A 2019 RCT found no significant difference between Epley maneuver and cinnarizine (25mg every 8 hours for 2 weeks) in symptom improvement (mean VAS scores: 1.66 vs 1.50, p=0.57) 2. This demonstrates that cinnarizine offers no advantage over proper repositioning.

• Betahistine: Multiple studies show conflicting results:

  • A 2025 meta-analysis of 8 RCTs (516 participants) found no clinically significant difference when adding betahistine to Epley maneuver for DHI scores, VAS scores at 1 week, or provocation maneuvers 3
  • A 2019 study directly compared repositioning alone versus repositioning plus betahistine (24mg twice daily for 10 days) and found no statistically significant differences in DHI scores 4
  • A 2026 systematic review concluded that betahistine evidence remains "limited, heterogeneous, and methodologically uncertain" and that routine or universal use is not supported 5

The Correct Treatment Approach

First-line treatment is canalith repositioning procedures (Epley maneuver for posterior canal BPPV, supine roll test for lateral canal BPPV) with success rates around 80% after 1-3 treatments 1.

When Medications May Be Considered (Not as First-Line):

If medications are used at all, they should only be for:

1. Acute nausea relief during the vertigo episode (vestibular suppressants) 1
2. Possibly for residual dizziness after successful CRP (not for primary treatment)

If Betahistine Is Used for Residual Dizziness:

Based on the limited evidence suggesting potential benefit only in the longer term 3:

• Dose: 24mg twice daily (48mg/day total) or 36-48mg/day divided 5, 3, 4
• Duration: 4 weeks minimum (1 week showed no benefit; 4 weeks showed some VAS improvement in meta-analysis) 3
• Indication: Only for persistent residual dizziness after successful CRP, not as primary treatment
• Expectation: Evidence is weak and inconsistent; many patients will not benefit 5

Critical Pitfalls to Avoid

1. Do not prescribe these medications instead of performing CRPs—this is the most common error and delays definitive treatment 1, 6

2. Avoid long-term prescriptions: A 2025 Dutch primary care study found that 32% of AVD prescriptions became long-term, with 88% prescribed for conditions other than Ménière's disease—this represents potentially inappropriate prescribing 6

3. Do not use for BPPV prophylaxis: There is no evidence that medications prevent BPPV recurrence 1

4. Recognize that medication use may mask the need for repeat CRPs: If symptoms persist, patients likely need additional repositioning maneuvers (2-3 treatments often needed), not medication 1

Clinical Algorithm

1. Diagnose BPPV with Dix-Hallpike test (posterior canal) or supine roll test (lateral canal) 1
2. Perform appropriate CRP immediately (Epley for posterior canal, barbecue roll for lateral canal) 1
3. Reassess in 1 week: If symptoms persist, repeat CRP (not medication) 1
4. Only if residual dizziness persists after successful CRP (negative repositioning test but ongoing non-positional dizziness): Consider betahistine 24mg twice daily for 4 weeks 3
5. Never use cinnarizine or betahistine as monotherapy or first-line treatment 2, 4

The evidence is clear: mechanical treatment for a mechanical problem. Medications do not address the underlying pathophysiology of displaced otoconia and should not delay or replace definitive CRP treatment.